Inventiva to Present Research on Digital Pathology at AASLD Congress
Inventiva, a biopharmaceutical company, will present four abstracts related to digital pathology at the upcoming American Association for the Study of Liver Diseases congress.
Inventiva's Participation at The Liver Meeting® 2025
Inventiva has announced its participation in the annual congress of the American Association for the Study of Liver Diseases (AASLD), The Liver Meeting® 2025, to be held in Washington D.C. from November 7 to 11, 2025. The company will present a total of four abstracts, all in the form of posters. The first, titled 'Comparison of digital images versus glass slides for the histopathological evaluation of liver biopsy samples according to the NASH-CRN scoring system for MASH', will be presented on November 8, 2025. The other presentations, scheduled for November 9, 2025, will include preclinical studies highlighting the therapeutic effects of lanifibranor, particularly its antifibrotic and anti-inflammatory properties.
Lanifibranor: Inventiva’s Leading Drug Candidate
Lanifibranor is Inventiva’s most advanced drug candidate. It is an orally administered small molecule designed to moderately and equipotently activate the three isoforms of the peroxisome proliferator-activated receptors (PPAR): PPAR?, PPAR?, and PPAR?. This activation aims to produce antifibrotic, anti-inflammatory, and various vascular and metabolic changes. Lanifibranor stands out as the only pan-PPAR agonist currently in clinical development. According to the company, its balanced profile could contribute to its observed safety and tolerance in clinical trials and preclinical studies. It has received 'Fast Track' and 'Breakthrough Therapy' designations from the FDA for the treatment of MASH.
Inventiva's Focus on Oral Therapies for MASH
Inventiva is focused on the development of oral therapies to treat metabolic dysfunction-associated steatohepatitis (MASH). The development and presentation of its research at international congresses such as AASLD underscore the importance placed on its work in this area. The choice to focus on digital pathology aligns with a growing trend in biomedical research aimed at enhancing the precision and efficiency of diagnostic evaluations. Inventiva’s booth will be located at number 745 during the congress, where the company will showcase its advancements and commitment to treating liver diseases.
